Search results for "nuclide"

showing 10 items of 397 documents

The Design and Sensitivity of JUNO's scintillator radiopurity pre-detector OSIRIS

2021

The European physical journal / C 81(11), 973 (2021). doi:10.1140/epjc/s10052-021-09544-4

Liquid scintillatorPhysics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and Detectorsscintillation counter: liquidmeasurement methodsQC770-798Astrophysics01 natural sciencesthorium: nuclidedesign [detector]neutrinoRadioactive purityPhysicsLow energy neutrinoJUNOliquid [scintillation counter]biologySettore FIS/01 - Fisica SperimentaleDetectorInstrumentation and Detectors (physics.ins-det)3. Good healthQB460-466Physics::Space Physicsnuclide [uranium]FOS: Physical sciencesScintillatornuclide [thorium]530NONuclear physicsPE2_2uranium: nuclideNuclear and particle physics. Atomic energy. Radioactivity0103 physical sciencesddc:530Sensitivity (control systems)[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]010306 general physicsJUNO neutrino physics liquid scintillatorEngineering (miscellaneous)background: radioactivitydetector: designMeasurement method010308 nuclear & particles physicsradioactivity [background]biology.organism_classificationsensitivityHigh Energy Physics::ExperimentReactor neutrinoOsiris
researchProduct

Radiopurity control in the NEXT-100 double beta decay experiment: procedures and initial measurements

2013

[EN] The "Neutrino Experiment with a Xenon Time-Projection Chamber" (NEXT) is intended to investigate the neutrinoless double beta decay of Xe-136, which requires a severe suppression of potential backgrounds. An extensive screening and material selection process is underway for NEXT since the control of the radiopurity levels of the materials to be used in the experimental set-up is a must for rare event searches. First measurements based on Glow Discharge Mass Spectrometry and gamma-ray spectroscopy using ultra-low background germanium detectors at the Laboratorio Subterraneo de Canfranc (Spain) are described here. Activity results for natural radioactive chains and other common radionucl…

MECANICA DE LOS MEDIOS CONTINUOS Y TEORIA DE ESTRUCTURASPhysics - Instrumentation and DetectorsGlow Discharge Mass SpectrometryPhysics::Instrumentation and Detectorschemistry.chemical_elementFOS: Physical sciencesGermanium01 natural sciences7. Clean energyTECNOLOGIA ELECTRONICANuclear physicsCambres d'ionitzacióXenonDouble beta decay0103 physical sciencesNuclear Experiment (nucl-ex)010306 general physicsNuclear ExperimentInstrumentationDetectors de radiacióMathematical PhysicsPhysicsRadionuclideRadiation calculationsIonization chambers010308 nuclear & particles physicsTime projection Chambers (TPC)Gamma detectors (scintillators CZT HPG HgI etc)FísicaInstrumentation and Detectors (physics.ins-det)chemistryNuclear countersNeutrino
researchProduct

Development of a [177Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy

2015

Painful bone lesions, both benign and metastatic, are often managed using conventional analgesics. However, the treatment response is not immediate and is often associated with side-effects. Radionuclide therapy is used for pain palliation in bone metastases as well as some benign neoplasms. Endoradiotherapy has direct impact on the pain-producing bone elements, and hence, response is significant, with minimal or no side-effects. A new potential compound for endoradiotherapy is [(177)Lu]BPAMD. It combines a highly affine bisphosphonate, covalently bridged with DOTA through an amide bond, with the low-energy β(-) emitting therapeutic radiolanthanide (177)Lu. For routine chemical application,…

MaleCancer ResearchTreatment responsePathologymedicine.medical_specialtymedicine.medical_treatmentPainBone NeoplasmsLutetiumBone and BonesPain palliationchemistry.chemical_compoundmedicineHumansDOTARadiology Nuclear Medicine and imagingBenign neoplasmsAgedRadioisotopesPharmacologyDiphosphonatesStaining and Labelingbusiness.industryGeneral MedicineBisphosphonateAmidesOncologychemistryBone lesionRadionuclide therapyReagent Kits DiagnosticRadiopharmaceuticalsNuclear medicinebusinessCancer Biotherapy and Radiopharmaceuticals
researchProduct

Radiolabelling and preliminary evaluation of 68Ga-tetrapyrrole derivatives as potential tracers for PET

2013

article i nfo Tetrapyrroles are multisided natural products which are of relevance in clinical medicine. Owing to their specific accumulation in tumour tissue, porphyrins, metalloporphyrins and chlorins have been used as in photodynamic therapy and optical imaging. Moreover, their specific uptake into inflammatory atheromatous plaques via LDL endocytosis has been reported. The present study is concerned with the synthesis of 68 Ga labelled porphyrin derivatives and an in vitro assessment of the utility of radiotracers in positron emission tomography. A set of five porphyrin derivatives were labelled using 68 Ga from a commercially obtained radionuclide generator. Dedicated post-processing o…

MaleCancer Researchmedicine.medical_treatmentGallium RadioisotopesPhotodynamic therapyEndocytosischemistry.chemical_compoundDrug StabilityRadioligandmedicineAnimalsHumansRadiology Nuclear Medicine and imagingRadiochemistrymedicine.diagnostic_testRadiochemistryBlood ProteinsPorphyrinTetrapyrroleIn vitroRatsTetrapyrroleschemistryBiochemistryPositron emission tomographyIsotope LabelingPositron-Emission TomographyMolecular MedicineRadionuclide GeneratorNuclear Medicine and Biology
researchProduct

Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior.

2015

Adolescence is characterized by drastic behavioral adaptations and comprises a particularly vulnerable period for the emergence of various psychiatric disorders. Growing evidence reveals that the pathophysiology of these disorders might derive from aberrations of normal neurodevelopmental changes in the adolescent brain. Understanding the molecular underpinnings of adolescent behavior is therefore critical for understanding the origin of psychopathology, but the molecular mechanisms that trigger adolescent behavior are unknown. Here, we hypothesize that the cannabinoid type-1 receptor (CB1R) may play a critical role in mediating adolescent behavior because enhanced endocannabinoid (eCB) sig…

MaleCannabinoid receptorAdolescentmedicine.medical_treatmentIn Vitro TechniquesImpulsivityMediatorRisk-TakingCocaineReceptor Cannabinoid CB1Sulfur IsotopesmedicineAnimalsHumansMaze LearningRadionuclide ImagingSocial BehaviorCannabinoid Receptor AntagonistsBehavior AnimalGeneral NeuroscienceNovelty seekingAge FactorsBrainArticlesPhenotypeEndocannabinoid systemCorpus StriatumRats Inbred F344RatsAdolescent BehaviorGuanosine 5'-O-(3-Thiotriphosphate)Models AnimalMutationExploratory BehaviorCannabinoid receptor antagonistCannabinoidmedicine.symptomRats TransgenicPsychologyNeuroscienceEndocannabinoidsThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Risk of Lung Cancer Mortality in Nuclear Workers from Internal Exposure to Alpha Particle-emitting Radionuclides

2017

Supplemental Digital Content is available in the text.

MaleLung NeoplasmsEpidemiology[SDV]Life Sciences [q-bio]chemistry.chemical_elementRadonSubstàncies radioactivesExtraction and Processing Industry030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBelgiumRisk FactorsEnvironmental healthOccupational ExposureMortalitatMedicineHumansLung Neoplasms/mortality; Neoplasms Radiation-Induced/mortality; Occupational Diseases/mortality; Radiation Exposure/adverse effectsMortalityLung cancerRadiometryCarcinogenCancerAgedRadionuclidebusiness.industryAlpha particleMiddle Agedmedicine.diseaseAlpha ParticlesPlutoniumUnited Kingdom3. Good healthchemistry030220 oncology & carcinogenesisCase-Control StudiesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGCàncer de pulmóUraniumFemaleOccupational exposureFranceLung cancerbusinessNuclear medicineRadioactive substances
researchProduct

Intraoperative localization of malignant pheochromocytoma by 123-i-metaiodobenzylguanidine single probe measurement

1988

Metaiodobenzylguanidine (MIBG) imaging is a well-established method for locating intra- and extraadrenal pheochromocytomas. We investigated whether preoperative injection of 123-I-MIBG might be useful for intraoperative staging of chromaffine tumor cells. This was performed in a 46-year-old patient in whom the diagnosis of a malignant pheochromocytoma had been established by 123-I-MIBG imaging and enhanced catecholamine secretion. The rationale for intraoperative staging in this patient was a discrepancy between computed tomography (CI) of the abdomen and the radionuclide imaging, because scintigraphy revealed a mass with MIBG uptake in the right lower abdomen that could not be visualized b…

MaleMalignant Pheochromocytomamedicine.medical_specialtyAdrenal Gland NeoplasmAdrenal Gland NeoplasmsPheochromocytomaScintigraphy3-IodobenzylguanidineIodine RadioisotopesPheochromocytomaDrug DiscoverymedicineHumansSingle probeNeoplasm MetastasisRadionuclide ImagingGenetics (clinical)medicine.diagnostic_testIodobenzenesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAbdominal mass3-Iodobenzylguanidinemedicine.anatomical_structureMolecular MedicineAbdomenRadiologymedicine.symptomNuclear medicinebusinessKlinische Wochenschrift
researchProduct

SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging☆

2008

Statistical comparisons of [(18)F]FDG PET scans between healthy subjects and patients with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI) using Statistical Parametric Mapping (SPM) usually require normalization of regional tracer uptake via ROIs defined using additional software. Here, we validate a simple SPM-based method for count normalization. FDG PET scans of 21 mild, 15 very mild AD, 11 aMCI patients and 15 age-matched controls were analyzed. First, we obtained relative increases in the whole patient sample compared to controls (i.e. areas relatively preserved in patients) with proportional scaling to the cerebral global mean (CGM). Next, average absolute counts…

MaleNormalization (statistics)Agingmedicine.medical_specialtyPathologyCognitive NeuroscienceLogistic regressionStatistical parametric mappingNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Internal medicineImage Interpretation Computer-AssistedmedicineHumansDementiaHealthy agingRadionuclide ImagingCognitive impairmentAgedRetrospective StudiesBrain Mappingmedicine.diagnostic_testBrainmedicine.diseaseNeurologyPositron emission tomographyCardiologyFemaleCognition DisordersPsychologyAlgorithmsNeuroImage
researchProduct

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

2019

Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyPeptide receptormedicine.medical_treatmentNeuroendocrine tumorsOctreotide030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyInternal medicineOrganometallic CompoundsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingAdverse effectCapecitabineAgedChemotherapybusiness.industryIncidence (epidemiology)Therapeutic effectChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumors030220 oncology & carcinogenesisConcomitantRadionuclide therapyFemaleRadiopharmaceuticalsbusinessClinical Nuclear Medicine
researchProduct

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

2019

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…

MaleOncologymedicine.medical_specialtyHigh-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapyLung NeoplasmsDatabases FactualSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsHigh-dose somatostatin analogNeuroendocrine tumorsOctreotideSomatostatin analogueTargeted therapySettore MED/13 - EndocrinologiaTargeted therapyEndocrinologyNeuroendocrine tumorStomach NeoplasmsInternal medicineDiabetes mellitusIntestinal NeoplasmsSequence of treatmentmedicineHumansEverolimusRetrospective StudiesChemotherapyEverolimusbusiness.industryDisease ManagementMiddle Agedmedicine.diseaseDiscontinuationPancreatic NeoplasmsNeuroendocrine TumorsRadionuclide therapyFemaleObservational studyPRRTSomatostatinbusinessmedicine.drug
researchProduct